KeyCorp reiterated their hold rating on shares of DaVita HealthCare Partners (NYSE:DVA) in a report published on Wednesday. KeyCorp also issued estimates for DaVita HealthCare Partners’ FY2018 earnings at $3.41 EPS.

A number of other research analysts have also weighed in on the stock. Wolfe Research raised shares of DaVita HealthCare Partners from a market perform rating to an outperform rating in a research note on Monday, October 23rd. Bank of America decreased their price target on shares of DaVita HealthCare Partners from $75.00 to $66.00 and set a neutral rating on the stock in a research note on Wednesday, November 8th. J P Morgan Chase & Co lowered shares of DaVita HealthCare Partners from a neutral rating to an underweight rating in a research note on Monday, October 9th. Zacks Investment Research lowered shares of DaVita HealthCare Partners from a hold rating to a sell rating in a research note on Wednesday, October 11th. Finally, Royal Bank Of Canada reissued a hold rating and issued a $64.00 target price on shares of DaVita HealthCare Partners in a research note on Wednesday, September 6th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has an average rating of Hold and an average target price of $69.88.

DaVita HealthCare Partners (NYSE DVA) opened at $67.71 on Wednesday. The firm has a market cap of $12,814.79, a PE ratio of 19.35, a P/E/G ratio of 13.65 and a beta of 0.97. DaVita HealthCare Partners has a 12 month low of $52.51 and a 12 month high of $70.16. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79.

DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). The company had revenue of $3.92 billion during the quarter, compared to analysts’ expectations of $3.91 billion. DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.31%. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.95 earnings per share. equities analysts anticipate that DaVita HealthCare Partners will post 3.42 earnings per share for the current fiscal year.

DaVita HealthCare Partners declared that its board has authorized a share buyback program on Tuesday, October 10th that allows the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DVA. Schroder Investment Management Group lifted its stake in DaVita HealthCare Partners by 769.0% in the 3rd quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock worth $25,387,000 after purchasing an additional 384,224 shares in the last quarter. Canada Pension Plan Investment Board raised its position in shares of DaVita HealthCare Partners by 33.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 387,370 shares of the company’s stock valued at $25,086,000 after buying an additional 96,282 shares during the period. Speece Thorson Capital Group Inc. raised its position in shares of DaVita HealthCare Partners by 14.5% during the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after buying an additional 40,667 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH raised its position in shares of DaVita HealthCare Partners by 1,987.3% during the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock valued at $2,448,000 after buying an additional 39,746 shares during the period. Finally, Airain ltd purchased a new stake in shares of DaVita HealthCare Partners during the 2nd quarter valued at approximately $2,234,000. 85.32% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “DaVita HealthCare Partners (DVA) Rating Reiterated by KeyCorp” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/10/davita-healthcare-partners-dva-rating-reiterated-by-keycorp.html.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.